Every 8-K that Astrana Health Inc. (ASTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ASTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASTH filings page.
Astrana Health, Inc. updated its corporate presentation and reported second-quarter 2026 revenue of $972.5 million, up 48% from the prior-year quarter, and Adjusted EBITDA of $68.9 million, compared with $48.1 million. Free cash flow was $92.9 million for the six months ended June 30, 2026.
Management raised full-year 2026 Adjusted EBITDA guidance to $255 million–$280 million, citing first-half outperformance, and reaffirmed revenue guidance of $3.8 billion–$4.1 billion and free cash flow guidance of $105 million–$132.5 million. General and administrative expenses were 5.6% of revenue in Q2 2026, versus 7.7% in Q2 2025; management expects to exit 2026 at approximately 6%.
The presentation describes approximately 1.5 million members in value-based arrangements, more than 20,000 providers and operations in 18 markets. Care Enablement had $340 million of revenue for the twelve months ended June 30, 2026, with a 43% gross margin and a 21% operating margin.
Astrana Health, Inc. disclosed a cybersecurity incident that it determined was material as of September 22, 2026. Its subsidiary detected unusual activity involving social-engineering attempts to obtain access to company systems. The company says certain private or confidential information on its servers was accessed and/or acquired without authorization, and it is assessing whether patient, employee, provider, business, financial, or intellectual-property information was affected.
Astrana responded by resetting affected credentials, restricting remote access tools, restoring certain systems from clean backups, and enhancing monitoring. Its investigation is ongoing; it has notified law enforcement and is notifying regulators and payer partners. The company cannot yet estimate the incident’s full potential impact, but currently does not expect a material effect on its financial condition or results of operations. Its cybersecurity insurance may cover certain losses.
Astrana Health, Inc. (ASTH) furnished an updated investor presentation outlining its AI-enabled, value-based care model, recent performance, and 2026 outlook. The company reports operating at scale with about 1.5 million members in value-based arrangements and more than 20,000 providers caring for these members across 16 markets.
Revenue for 2025 was $3.18 billion with Adjusted EBITDA of $205.4 million, and the company reiterates a medium-term goal of 15–20% annual Adjusted EBITDA growth. For 2026, guidance calls for total revenue of $3.8–$4.1 billion, Adjusted EBITDA of $255–$280 million, and free cash flow of $105–$132.5 million. Q2 2026 revenue was $972.5 million with Adjusted EBITDA of $68.9 million and a 7.1% Adjusted EBITDA margin, supported by G&A improving 210 basis points year over year to 5.6% of revenue. Astrana highlights an AI-native operating platform that automates prior authorizations and claims adjudication, and emphasizes a continued shift toward full-risk contracts, which represented 81% of Q2 2026 capitation revenue, while noting a previously disclosed material weakness in internal control over financial reporting.
Astrana Health, Inc. reported strong results for the quarter ended June 30, 2026, with total revenue of $972.5 million, up 49% from a year earlier, driven primarily by capitation revenue. Net income attributable to Astrana increased to $19.7 million, and diluted EPS doubled to $0.40.
Non-GAAP performance was also robust: Adjusted EBITDA rose 43% to $68.9 million, maintaining a 7% margin, while adjusted diluted EPS reached a record-high $0.80. For the first half of 2026, free cash flow was $92.9 million on operating cash flow of $100.8 million.
The company raised its 2026 outlook, guiding to $3.8–$4.1 billion in revenue and $255–$280 million of Adjusted EBITDA, and expects free cash flow of $105–$132.5 million. Astrana highlighted its value-based model, with about 1.5 million patients and 81% of Q2 capitation revenue from full-risk arrangements. Management also refers to an existing material weakness in internal control over financial reporting and its intention to remediate it.
Astrana Health, Inc. reported that its accountable care organizations generated $120.4 million in gross shared savings in the 2024 performance year. All eight affiliated ACOs achieved net shared savings, including five in the Medicare Shared Savings Program and three in the ACO REACH model.
The company supports more than 20,000 providers caring for approximately 1.55 million patients through partnerships with over 20 payers nationwide. For the year ended December 31, 2025, Astrana recorded $3.18 billion in revenue, $24.1 million in net income, $123.1 million in EBITDA, and $205.4 million in Adjusted EBITDA. In the first quarter of 2026, revenue grew 56% year over year, reflecting continued expansion of its physician-centric, AI-enabled value-based care platform.
Astrana Health, Inc. announced that Chief Accounting Officer and principal accounting officer Glenn Sobotka will retire from his positions effective August 7, 2026. The company states his retirement is not due to any disagreement regarding operations, policies, or practices.
John Vong, currently Group Vice President, Accounting, has been appointed Senior Vice President – Accounting effective July 1, 2026 and will become principal accounting officer on August 7, 2026. Vong, age 52, has extensive prior experience in senior accounting roles at Astrana Health and Prospect Medical Systems. Effective July 1, 2026, his annual base salary will be $320,000. The company notes there are no related-party transactions or family relationships requiring disclosure.
Astrana Health, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which increases the shares of common stock reserved for issuance by 1,000,000 shares and extends the plan’s term until March 24, 2036. All director nominees were elected and the appointment of the independent registered public accounting firm was ratified. An advisory vote on executive compensation passed, and the equity plan received strong support, with 34,679,879 votes in favor. The meeting had a quorum, with 43,772,595 shares represented, about 78.6% of the 55,713,532 shares outstanding as of the record date.
Astrana Health, Inc. disclosed that its Chief Medical Officer, Dinesh Kumar, M.D., has notified the company of his intention to resign. His resignation will be effective June 1, 2026. The company states that Dr. Kumar’s decision is not due to any disagreement with Astrana Health. The filing notes the company’s appreciation for his contributions and extends well wishes for his future endeavors.
Astrana Health, Inc. furnished an updated corporate investor presentation for May 2026. The company plans to use these slides at conferences and meetings, and has attached them as Exhibit 99.1. The material is expressly treated as furnished, not filed, which limits potential securities law liabilities.
The accompanying presentation outlines Astrana’s business mix across Medicare, Medicaid, commercial and other third-party payers, and highlights revenue categories such as capitation, risk pool settlements, management fees and fee-for-service. It also includes a chart of general and administrative expenses and G&A as a percentage of revenue over 2023–2026E.
Astrana Health, Inc. reported strong first quarter 2026 results, with total revenue of $965,100 (thousands), up 56% from the prior-year quarter. Net income attributable to Astrana was $14,436 (thousands), and diluted EPS doubled to $0.29.
Non-GAAP performance also improved, as Adjusted EBITDA rose to $66,298 (thousands), a year-over-year increase of 82%, and Adjusted EPS – diluted reached $0.74. Free cash flow increased to $64,056 (thousands), up 372% year over year, while cash and cash equivalents grew to $478,383 (thousands).
The company reaffirmed 2026 guidance, targeting total revenue between $3,800,000 and $4,100,000 (thousands), Adjusted EBITDA between $250,000 and $280,000 (thousands), and free cash flow between $105,000 and $132,500 (thousands). Management highlighted growth in full-risk value-based arrangements and continued deployment of its AI-enabled care platform.
Astrana Health, Inc. filed an 8-K providing interim unaudited financial statements for PHP Holdings, LLC & Rhode Island Market and unaudited pro forma results reflecting Astrana’s acquisition of this business.
For the nine months ended June 30, 2025, the acquired business generated $961.8 million in net revenue, primarily from capitation of $830.4 million, but reported a net loss of $38.7 million. Total assets were $336.5 million and total liabilities $1.57 billion, including $1.26 billion of debt and $75.3 million of redeemable convertible preferred stock, resulting in a significant members’ deficit.
The notes explain PHP Holdings’ highly capitated model, major credit facilities such as the PhysicianCo Term Loan and Phase I Convertible Note, and confirm Astrana closed the acquisition of Alta Newport Hospital, Prospect Health Plan and related assets for $674.9 million on July 1, 2025.
Astrana Health furnished an updated investor presentation outlining its value-based care model, recent growth, and financial outlook. For 2025, total revenue was $3.18 billion with $205.4 million of Adjusted EBITDA and $104.5 million of free cash flow. The company serves 1.6 million members in value-based arrangements through more than 20,000 providers across sixteen markets, and is shifting more business into full-risk capitation. For 2026, it guides to revenue of $3.8–$4.1 billion, Adjusted EBITDA of $250–$280 million, and free cash flow of $105–$132.5 million. Astrana also discusses an expected material weakness in internal control over financial reporting and its plan to file the 2025 Form 10-K by the Form 12b-25 extension deadline.
Astrana Health, Inc. reported strong 2025 growth, with total revenue of $3.18 billion, up 56% year over year and at the high end of guidance. Adjusted EBITDA reached $205.4 million and free cash flow was $104.5 million, supported by higher capitation revenue and expanding Care Partners and Care Enablement contributions.
Adjusted EPS diluted rose to $2.20 from $1.94, although GAAP net income fell to $24.1 million from $49.9 million as interest expense and acquisition-related costs increased. The company issued 2026 guidance for revenue of $3.8–$4.1 billion and Adjusted EBITDA of $250–$280 million, implying further double-digit growth.
Astrana will file Form 12b-25 to extend its 2025 Form 10‑K deadline and expects to report a material weakness in internal control over financial reporting related to acquisition and purchase accounting processes, while stating it does not reflect a material misstatement or restatements. The board doubled the share repurchase authorization from $50 million to $100 million; $35.9 million remained available as of December 31, 2025 after repurchasing 633,844 shares in the fourth quarter.
Astrana Health, Inc. furnished an updated corporate investor presentation that it plans to use at conferences and meetings. The slide deck, dated January 2026, is attached as Exhibit 99.1 and is provided for informational purposes only.
The company states that this material is being furnished rather than filed, which means it is not subject to certain liability provisions under securities laws and will not automatically be incorporated into other regulatory filings. The presentation contains forward-looking statements, and Astrana Health refers readers to its most recent annual and quarterly reports for a discussion of risks that could cause actual results to differ.
Astrana Health, Inc. furnished an update on its financial results for the three and nine months ended September 30, 2025. The company issued a press release and made an earnings presentation available, each furnished as exhibits.
A conference call and webcast are scheduled for 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time on November 6, 2025 to discuss the results. The materials are furnished, not filed, and are available on the investor relations site and as Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental data).
Astrana Health, Inc. reports it has completed the acquisition of all outstanding equity interests of Prospect Health Plan, Inc. and Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center), and substantially all assets of certain direct and indirect subsidiaries of PHP Holdings, LLC, pursuant to an Asset and Equity Purchase Agreement dated November 8, 2024. The filing amends a prior Current Report on Form 8-K to incorporate Exhibits 99.1, 99.2 and 99.3 by reference.
The filing states that Unaudited Pro Forma Financial Statements are presented to give effect to the Transaction and related transactions. The document does not state purchase price, consideration, pro forma amounts, or other financial detail in the text provided here.